[REUTERS]
(Reuters) – An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.
The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller study that, while positive, were not robust enough to convince the committee that they could be reproduced.